These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30836444)

  • 21. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.
    Bergesio F; Ciciani AM; Manganaro M; Palladini G; Santostefano M; Brugnano R; Di Palma AM; Gallo M; Rosati A; Tosi PL; Salvadori M;
    Nephrol Dial Transplant; 2008 Mar; 23(3):941-51. PubMed ID: 17951308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience.
    Ozawa M; Komatsuda A; Ohtani H; Nara M; Sato R; Togashi M; Takahashi N; Wakui H
    Clin Exp Nephrol; 2017 Apr; 21(2):212-227. PubMed ID: 27116248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.
    Kumar S; Dispenzieri A; Katzmann JA; Larson DR; Colby CL; Lacy MQ; Hayman SR; Buadi FK; Leung N; Zeldenrust SR; Ramirez-Alvarado M; Clark RJ; Kyle RA; Rajkumar SV; Gertz MA
    Blood; 2010 Dec; 116(24):5126-9. PubMed ID: 20798235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.
    Sachchithanantham S; Berlanga O; Alvi A; Mahmood SA; Lachmann HJ; Gillmore JD; Hawkins PN; Harding S; Wechalekar AD
    Br J Haematol; 2017 Nov; 179(4):575-585. PubMed ID: 28990174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation.
    Dittus C; Uwumugambi N; Sun F; Sloan JM; Sanchorawala V
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1729-1732. PubMed ID: 27296954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis.
    Oke O; Sethi T; Goodman S; Phillips S; Decker I; Rubinstein S; Concepcion B; Horst S; Jagasia M; Kassim A; Harrell SL; Langone A; Lenihan D; Rawling KT; Slosky D; Cornell RF
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1473-1477. PubMed ID: 28546074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study.
    Jain T; Kosiorek HE; Kung ST; Shah VS; Dueck AC; Gonzalez-Calle V; Luft S; Reeder CB; Adams R; Noel P; Larsen JT; Mikhael J; Bergsagel L; Stewart AK; Fonseca R
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):486-492.e1. PubMed ID: 29753692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A risk stratification for systemic immunoglobulin light-chain amyloidosis with renal involvement.
    Li T; Huang X; Wang Q; Zhao L; Ren G; Chen W; Zheng C; Zhou M; Jiang Q; Yin R; Liu Z
    Br J Haematol; 2019 Nov; 187(4):459-469. PubMed ID: 31348519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A clinical retrospective analysis of newly diagnosed multiple myeloma patients with systemic light chain amyloidosis].
    Liu Y; You HY; Yan LZ; Jin S; Shang JJ; Shi XL; Yan S; Yao WQ; Wu DP; Liu W; Fu CC
    Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):330-335. PubMed ID: 35680633
    [No Abstract]   [Full Text] [Related]  

  • 30. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
    Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
    Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement.
    Huang X; Wang Q; Chen W; Ren G; Liu Z
    Amyloid; 2016; 23(1):51-7. PubMed ID: 26862817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib.
    Manwani R; Cohen O; Sharpley F; Mahmood S; Sachchithanantham S; Foard D; Lachmann HJ; Quarta C; Fontana M; Gillmore JD; Whelan C; Hawkins PN; Wechalekar AD
    Blood; 2019 Dec; 134(25):2271-2280. PubMed ID: 31578202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
    Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
    Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of light chain isotype on clinical features and outcomes in systemic AL amyloidosis.
    Hopson MB; Bhutani D; Sarkaria S; Maurer MS; Griffin JM; Mapara M; Lentzsch S; Chakraborty R
    Leuk Lymphoma; 2022 Sep; 63(9):2109-2113. PubMed ID: 35465769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor.
    Rezk T; Lachmann HJ; Fontana M; Sachchithanantham S; Mahmood S; Petrie A; Whelan CJ; Pinney JH; Foard D; Lane T; Youngstein T; Wechalekar AD; Bass P; Hawkins PN; Gillmore JD
    Kidney Int; 2017 Dec; 92(6):1476-1483. PubMed ID: 28729034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
    Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
    Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis.
    Dittrich T; Bochtler T; Kimmich C; Becker N; Jauch A; Goldschmidt H; Ho AD; Hegenbart U; Schönland SO
    Blood; 2017 Aug; 130(5):632-642. PubMed ID: 28550043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of autologous stem cell transplant for cardiac AL-amyloidosis and cardiac light chain deposition disease.
    Abdallah AA; Alapat D; Kaur V; Atrash S
    J Oncol Pharm Pract; 2020 Jul; 26(5):1128-1133. PubMed ID: 31795821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation.
    Sidiqi MH; Aljama MA; Jevremovic D; Morice WG; Timm M; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Gonsalves WI; Kumar S; Kapoor P; Kourelis T; Leung N; Hogan WJ; Gertz M
    Haematologica; 2018 Jul; 103(7):1229-1234. PubMed ID: 29674497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.